EMA Authorised: Tandemact (pioglitazone;glimepiride) — CHEPLAPHARM Arzneimittel GmbH

View source ↗

Summary

EMA has authorised Tandemact (pioglitazone; glimepiride) for type 2 diabetes mellitus under CHEPLAPHARM Arzneimittel GmbH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Tandemact
• pioglitazone; glimepiride (pioglitazone; glimepiride)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: CHEPLAPHARM Arzneimittel GmbH. Decision date: 07/09/2023